DDInter840 DDInter915
A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients.
Indacaterol is a novel, ultra-long-acting, rapid onset β(2)-adrenoceptor agonist developed for Novartis for the once-daily management of asthma and chronic obstructive pulmonary disease. It was approved by the European Medicines Agency (EMA) on 30 November 2009 and by the FDA on 1 July 2011. It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.
Granisetron {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Indacaterol
Granisetron {u} (Compound) causes {v} (Side Effect) Atrial fibrillation
Atrial fibrillation {u} (Side Effect) is caused by {v} (Compound) Indacaterol
Granisetron {u} (Compound) downregulates {v} (Gene) TXNDC9
TXNDC9 {u} (Gene) is downregulated by {v} (Compound) Procaterol
Procaterol {u} (Compound) resembles {v} (Compound) Indacaterol
Granisetron {u} (Compound) downregulates {v} (Gene) EBNA1BP2
EBNA1BP2 {u} (Gene) is regulated by {v} (Gene) UGT1A1
UGT1A1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salbutamol
Salbutamol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orciprenaline
Orciprenaline {u} (Compound) treats {v} (Disease) asthma
asthma {u} (Disease) is treated by {v} (Compound) Indacaterol
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Formoterol
Formoterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Adrenergic beta2-Agonists {u} (Pharmacologic Class) includes {v} (Compound) Indacaterol
Granisetron {u} may lead to a major life threatening interaction when taken with {v} Sotalol
Sotalol {u} (Compound) binds {v} (Gene) ADRB1
ADRB1 {u} (Gene) is bound by {v} (Compound) Indacaterol
Granisetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orciprenaline
Orciprenaline {u} (Compound) binds {v} (Gene) ADRB2
ADRB2 {u} (Gene) is bound by {v} (Compound) Indacaterol
Granisetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indacaterol (Compound)
Granisetron (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Indacaterol (Compound)
Granisetron (Compound) downregulates TXNDC9 (Gene) and TXNDC9 (Gene) is downregulated by Procaterol (Compound) and Procaterol (Compound) resembles Indacaterol (Compound)
Granisetron (Compound) downregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is regulated by UGT1A1 (Gene) and UGT1A1 (Gene) is bound by Indacaterol (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline (Compound) treats asthma (Disease) and asthma (Disease) is treated by Indacaterol (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class) and Adrenergic beta2-Agonists (Pharmacologic Class) includes Indacaterol (Compound)
Granisetron may lead to a major life threatening interaction when taken with Sotalol and Sotalol (Compound) binds ADRB1 (Gene) and ADRB1 (Gene) is bound by Indacaterol (Compound)
Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is bound by Indacaterol (Compound)